体内
蛋白酶
效力
体外
IC50型
病毒学
病毒
蛋白酶抑制剂(药理学)
药理学
药品
生物利用度
病毒复制
化学
生物
酶
病毒载量
生物化学
生物技术
抗逆转录病毒疗法
作者
Baoxue Quan,Huiping Shuai,Anjie Xia,Yuxin Hou,Rui Zeng,Xinlei Liu,Guifeng Lin,Jingxin Qiao,Wen-Pei Li,Falu Wang,Kai Wang,Ren-Jie Zhou,Terrence Tsz‐Tai Yuen,Mingxin Chen,Chaemin Yoon,Ming Wu,Shiyu Zhang,Chong Huang,Yifei Wang,Wei Yang
标识
DOI:10.1038/s41564-022-01119-7
摘要
Emerging SARS-CoV-2 variants continue to cause waves of new infections globally. Developing effective antivirals against SARS-CoV-2 and its variants is an urgent task. The main protease (Mpro) of SARS-CoV-2 is an attractive drug target because of its central role in viral replication and its conservation among variants. We herein report a series of potent α-ketoamide-containing Mpro inhibitors obtained using the Ugi four-component reaction. The prioritized compound, Y180, showed an IC50 of 8.1 nM against SARS-CoV-2 Mpro and had oral bioavailability of 92.9%, 31.9% and 85.7% in mice, rats and dogs, respectively. Y180 protected against wild-type SARS-CoV-2, B.1.1.7 (Alpha), B.1.617.1 (Kappa) and P.3 (Theta), with EC50 of 11.4, 20.3, 34.4 and 23.7 nM, respectively. Oral treatment with Y180 displayed a remarkable antiviral potency and substantially ameliorated the virus-induced tissue damage in both nasal turbinate and lung of B.1.1.7-infected K18-human ACE2 (K18-hACE2) transgenic mice. Therapeutic treatment with Y180 improved the survival of mice from 0 to 44.4% (P = 0.0086) upon B.1.617.1 infection in the lethal infection model. Importantly, Y180 was also highly effective against the B.1.1.529 (Omicron) variant both in vitro and in vivo. Overall, our study provides a promising lead compound for oral drug development against SARS-CoV-2. An inhibitor of the SARS-CoV-2 main protease (Mpro), Y180, showed therapeutic efficacy against wild-type SARS-CoV-2 and its variants including Omicron after oral administration and improved survival in a humanized mouse model.
科研通智能强力驱动
Strongly Powered by AbleSci AI